Free Trial
NYSE:NVO

Novo Nordisk A/S (NVO) Stock Price, News & Analysis

$143.13
+0.76 (+0.53%)
(As of 07/8/2024 ET)
Today's Range
$142.18
$143.69
50-Day Range
$123.08
$146.90
52-Week Range
$75.56
$148.15
Volume
2.91 million shs
Average Volume
3.46 million shs
Market Capitalization
$642.30 billion
P/E Ratio
49.36
Dividend Yield
0.93%
Price Target
$145.67

Novo Nordisk A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
1.8% Upside
$145.67 Price Target
Short Interest
Healthy
0.10% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.41mentions of Novo Nordisk A/S in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.29%
From $3.44 to $4.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

439th out of 876 stocks

Pharmaceutical Preparations Industry

198th out of 416 stocks

NVO stock logo

About Novo Nordisk A/S Stock (NYSE:NVO)

Novo Nordisk A/S is a global healthcare company specializing in the research, development, production, and marketing of pharmaceutical products to treat diabetes, obesity, and other chronic diseases. The company was founded in 1923 in Denmark and is headquartered in Bagsværd, Denmark.

Novo Nordisk has operations in more than 80 countries, including production facilities in nine countries, and employs approximately 48,500 people worldwide.

Novo Nordisk's mission is to discover and develop innovative medicines to help people with chronic diseases lead longer, healthier lives. The company's key therapeutic areas include diabetes, obesity, hemophilia, growth hormone therapy, and other severe chronic diseases. Novo Nordisk is the world's largest producer of insulin and has been at the forefront of diabetes care for more than 95 years.

Lars Fruergaard Jørgensen is the President and CEO of Novo Nordisk A/S, a position he has held since 2017. Jørgensen joined Novo Nordisk in 1991 and has held various management positions, including Executive Vice President and Head of Corporate Development, Strategy and Biopharmaceuticals.

Novo Nordisk has consistently delivered strong financial performance over the past few years. Novo Nordisk's profit margin has remained consistently high, with a net margin of approximately 30%. In terms of debt, Novo Nordisk has maintained a conservative approach. Novo Nordisk's debt has kept pace with its assets for several years. The company's cash reserves have not always been healthy, but in 2022 Novo Nordisk made a profit for the first time since 2018.

Novo Nordisk's valuation metrics compare favorably to industry peers. It has a price-to-earnings ratio in line with its peers but a price-to-book ratio significantly higher than the industry average. Novo Nordisk's high P/B ratio reflects its strong brand, market position, and financial performance.

Novo Nordisk's stock has performed well over the past few years, with a 3-year annualized return of around 23%. The stock price has shown some volatility, with significant price movements in response to regulatory and market news related to diabetes and obesity markets. 

Novo Nordisk operates in the highly competitive and rapidly evolving pharmaceutical industry, specifically in diabetes and obesity markets. The global diabetes market is expected to grow at a CAGR of 5.7% from 2022 to 2027, driven by the increasing prevalence of diabetes, especially in emerging markets, and the growing demand for innovative diabetes treatments. In the obesity market, the global prevalence of obesity has been steadily increasing, and it is expected to continue to rise, driving demand for effective obesity treatments.

Novo Nordisk faces intense competition from several large and small pharmaceutical companies in the diabetes and obesity markets. The company's main competitors in the diabetes market include Sanofi, Eli Lilly, and AstraZeneca, while its main competitors in the obesity market include Roche, Novartis, and Eisai.

The company's competitive position is based on factors such as the quality and effectiveness of its products, its research and development capabilities, its brand reputation, and ability to adapt to changing market dynamics.

Novo Nordisk is also subject to various regulatory and political issues that can impact its operations and financial performance. The company must comply with strict regulatory requirements in each country it operates, including the US FDA and the European Medicines Agency. Changes in regulatory requirements, such as changes to reimbursement policies, can significantly impact the company's financial performance.

Novo Nordisk has several growth opportunities to pursue in the coming years. The company is investing heavily in research and development to develop new and innovative treatments for diabetes and obesity, as well as other chronic diseases. Novo Nordisk has a strong pipeline of potential products in development, including GLP-1 receptor agonists, which have shown promise in clinical trials for treating obesity.

The company also expands in emerging markets, such as China and India, with significant and growing demand for diabetes and obesity treatments. Novo Nordisk has established partnerships with local companies in these markets to help drive growth and increase product access.

Novo Nordisk has pursued acquisitions and partnerships to expand its product offerings and capabilities. In 2021, the company acquired Prothena's ATTR amyloidosis program, a potential treatment for a rare and debilitating disease. This acquisition will strengthen Novo Nordisk's position in the rare disease market.

Novo Nordisk faces several risks and challenges that could impact its operations and financial performance. The company's success is heavily dependent on the success of its products in the diabetes and obesity markets, and any setbacks in clinical trials or product launches could significantly impact its financial performance.

In addition, Novo Nordisk faces regulatory and political risks, as changes in regulations or policies could impact its ability to operate or sell its products in specific markets. The company is also subject to intellectual property risks, as competitors may seek to challenge its patents and market their products.

Novo Nordisk also faces risks related to supply chain disruptions and production delays, as well as cybersecurity and data privacy risks.

NVO Stock Price History

NVO Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 7/1 - 7/5 (NVO)
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
syringes, pills, fat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? (NVO)
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.
Logo sign of Pharmaceutical Corporation Pfizer building
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes (NVO)
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Eli Lilly logo on smartphone screen with stock market background
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market (NVO)
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Novo Nordisk A/S - share repurchase programme
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.
Novo Nordisk: Buy On Dips
Novo Nordisk A/S (NYSE:NVO) Shares Gap Down to $145.42
The 7 Best Stocks to Buy in July 2024
Novo Nordisk A/S (NYSE:NVO) Trading Up 1.5%
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
7/09/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
63,370
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$145.67
High Stock Price Target
$163.00
Low Stock Price Target
$115.00
Potential Upside/Downside
+1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$12.15 billion
Pretax Margin
45.82%

Debt

Sales & Book Value

Annual Sales
$33.71 billion
Cash Flow
$3.03 per share
Book Value
$3.45 per share

Miscellaneous

Outstanding Shares
4,487,530,000
Free Float
4,484,391,000
Market Cap
$642.30 billion
Optionable
Optionable
Beta
0.41

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Novo Nordisk:

  • Novo Nordisk has consistently shown strong financial performance, with a return on equity of 91.70% and a net margin of 36.56% in the latest quarter.
  • The company's stock price has been steadily increasing, trading up 2.5% recently, reaching $142.41.
  • Novo Nordisk has a diverse product portfolio in the pharmaceutical industry, with a strong presence in various regions globally, providing stability and growth potential.
  • Analysts have given the stock a consensus target price of $145.67, indicating potential for further growth.
  • The company has a solid track record of beating earnings estimates, as seen in the latest quarterly report where it surpassed expectations by $0.06 per share.

Cons

Investors should be bearish about investing in Novo Nordisk for these reasons:

  • Novo Nordisk's stock has a relatively high price-to-earnings ratio of 49.09, which may indicate an overvaluation compared to industry peers.
  • The company's beta of 0.41 suggests lower volatility compared to the market average, potentially limiting short-term trading opportunities for investors seeking higher returns.
  • Novo Nordisk's debt-to-equity ratio of 0.17 may raise concerns about the company's leverage and financial risk management strategies.
  • While the company has shown strong financials, the pharmaceutical industry is subject to regulatory changes and patent expirations that could impact future revenue streams.
  • Investors should consider the competitive landscape in the pharmaceutical sector, as Novo Nordisk faces competition from other major players in the market.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

NVO Stock Analysis - Frequently Asked Questions

How have NVO shares performed this year?

Novo Nordisk A/S's stock was trading at $103.45 at the beginning of 2024. Since then, NVO stock has increased by 38.4% and is now trading at $143.13.
View the best growth stocks for 2024 here
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Thursday, May, 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to analysts' expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a trailing twelve-month return on equity of 91.70%.

When did Novo Nordisk A/S's stock split?

Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023. The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were issued to shareholders after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Novo Nordisk A/S have any subsidiaries?

Novo Nordisk A/S subsidiaries include these companies: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more.

Who are Novo Nordisk A/S's major shareholders?

Top institutional shareholders of Novo Nordisk A/S include Beese Fulmer Investment Management Inc., Birch Capital Management LLC, ST Germain D J Co. Inc. and Boston Common Asset Management LLC.
View institutional ownership trends
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA) and QUALCOMM (QCOM).

This page (NYSE:NVO) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners